Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04431258 · ClinicalTrials.gov registry record · Phase 1

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

A Phase 1 study of Pancreatic Cancer, sponsored by Ability Pharmaceuticals SL.

Completed
Registry status
Phase 1
Development phase
150
Enrollment target
20
Study locations

NCT04431258 is a Phase 1 study of Pancreatic Cancer that has completed, run by Ability Pharmaceuticals SL. The registered enrollment target is 150 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04431258, a Phase 1 study of Pancreatic Cancer, has completed, sponsored by Ability Pharmaceuticals SL.

COMPLETED
Registry status
Phase 1
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic. Funded by: FDA OOPD (Grant #FD-R-006817-01), H2020 EIC Accelerator (Grant #954825) and Ability Pharmaceuticals SL.

Conditions Studied

Pancreatic Cancer

Interventions

  • DRUG Placebo
  • DRUG Folfirinox
  • DRUG ABTL0812

Study Locations (20)

Other

  • CGFL Dijon - Dijon
  • Institute Paoli-Calmettes - Marseille
  • Institut Gustave Roussy - Villejuif
  • Rabam MC - Haifa
  • Shaare Zedek MC - Jerusalem
  • Sheba MC - Ramat Gan
  • Hospital General Universitario Dr. Balmis - Alicante
  • Hospital Quiron Salud - Barcelona
  • Vall d'Hebron University Hospital - Barcelona
  • ICO Girona - Girona
  • Hospital Universitari Arnau de Vilanova - Lleida
  • Hospital Gregorio Marañón - Madrid
  • Hospital Universitario 12 de Octubre - Madrid
  • Hospital General Universitario Morales Meseguer - Murcia

California

  • Cedars Sinai - Los Angeles

Kansas

  • University of Kansas Cancer Center - Westwood

Massachusetts

  • Massachusetts General Hospital - Boston

Ohio

  • University of Cincinnati - Cincinnati

Barcelona

  • ICO Badalona - Badalona

Galicia

  • Centro Oncológico de Galicia - A Coruña

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2021-05-06
Est. Completion 2024-01-10
Phase Phase 1

Sponsor

Ability Pharmaceuticals SL

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04431258

The ClinicalTrials.gov registry entry for NCT04431258 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (62% lower). The listed sponsor is Ability Pharmaceuticals SL, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT04431258 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, California, Kansas.

Frequently Asked Questions

What is clinical trial NCT04431258 about?

NCT04431258 is a clinical study titled "ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study". A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic. Funded by: FDA OOPD (Grant #FD-R-006817-01), H2020 EIC Accelerator (Grant #954825) and Ability Phar...

What is the current status of trial NCT04431258?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2021-05-06. Estimated completion is 2024-01-10.

What conditions does trial NCT04431258 study?

This clinical trial studies the following conditions: Pancreatic Cancer.

What interventions are being tested in trial NCT04431258?

The interventions under investigation include: Placebo (DRUG), Folfirinox (DRUG), ABTL0812 (DRUG).

Who is sponsoring clinical trial NCT04431258?

This trial is sponsored by Ability Pharmaceuticals SL, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04431258 being conducted?

This trial has 20 study locations across California, Kansas, Massachusetts, Ohio, Barcelona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pancreatic Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Pancreatic Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.